Relatively low-dose infliximab (3 mg/kg ... [114] Golimumab, a new human anti-TNF monoclonal antibody, at 50 and 100 mg doses, also inhibited psoriatic artritic and skin lesion and improved ...
Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback